CO2 emissions: 1,500 kilotons (1,513)
Water Intake/Use: Use: 89.8M cubic meters (83.1M)
Nonhazardous waste: 94.3 kilotons (89.31)
Hazardous waste: 182.26 kilotons (156.86)
Energy: 17.45M gigajoules (17.01M)
Novartis is doing some big thinking about drug-making improvements that promise environmental and sustainability benefits. The Novartis-MIT Center for Continuous Manufacturing has a mission to get drug-making out of the batch era, in which further efficiency gains of any real significance now seem unlikely.
The collaboration envisions integrated continuous manufacturing with no process interruptions. Quality by Design principles and new product development processes will require new facility layouts and changes in the technical skills of those who run the processes.
Novartis captured the bronze in CRD Analytics' current Global 1000 Sustainable Performance Leaders list, taking a tumble from the top spot now held by Merck. The drugmaker participates in the EPA's Energy Star Focus on Energy Efficiency in Pharmaceutical Manufacturing.